Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HCB 101

Next Previous
Drug Profile

HCB 101

Alternative Names: HCB-101; HLX-701; SIRPα-Fc fusion protein - HanchorBio

Latest Information Update: 10 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HanchorBio
  • Developer HanchorBio; Shanghai Henlius Biotech
  • Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action CD47 antigen inhibitors; Phagocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Haematological malignancies; Solid tumours
  • Phase I/II Colorectal cancer; Non-small cell lung cancer
  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 08 Jul 2026 FBD Biologics signs a strategic memorandum of understanding with InxMed (Shanghai) for HCB 101 for Cancer
  • 07 Jul 2026 Kaohsiung Medical University Chung-Ho Memorial Hospital and FBD Biologics Limited plans a phase I/II trial for Adenocarcinoma (Combination therapy, Metastatic diseases, Late-stage diseases; Inoperable/Unresectable, First line therapy) (Parenteral) (NCT07680569)
  • 02 Jun 2026 Efficacy and pharmacokinetics data from a phase I trial in Solid tumours presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top